SCPS News and Press, Scopus BioPharma Inc. From 05/24/21

CpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope A Phase 1 Clinical Trial Will be Initiated at City of Hope NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the ap...

Scopus BioPharma ([[SCPS]] +4.5%) has submitted an investigational new drug application ((IND)) to the FDA for its immuno-oncology RNA therapy for the treatment of multiple cancers.The IND filing is a key milestone for the planned Phase 1 clinical trial for B-cell non-Hodgkin lymphoma to...

Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate Drug Candidate is Distinctive RNA Therapy and Immunotherapy Developed at City of Hope for Treatment of Multiple Cancers IND Filing a Key Milestone for Planned Phase 1 Clinical Trial to be Initiated at C...

Scopus BioPharma Announces Closing of Underwriters' Over-Allotment Option in Full Brings Total Follow-On Public Offering Proceeds to $10.35 Million PR Newswire NEW YORK , Feb. 10, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced t...

Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million PR Newswire NEW YORK , Feb. 8, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced that the underwriters of the compan...

Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering PR Newswire NEW YORK , Jan. 29, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the closing of a $9 million follow-on public offering.  The offerin...

Gainers: [[NVAX]] +20.9%. [[SWKS]] +14.8%. [[WDC]] +10.2%. [[SCPS]] +8.9%. [[BBBY]] +8.5%.Losers: [[GSIT]] -20.8%. [[SNDE]] -17.9%. [[STIM]] -4.9%. [[FIZZ]] -4.2%. [[CRTX]] -3.7%. For further details see: NVAX, WDC, GSIT and FIZZ among after-hours movers

Scopus BioPharma Announces Exchange Offer Exchange Would Provide Incentives for Long-Term Ownership by Existing and Prospective New Investors PR Newswire NEW YORK , Jan. 27, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced that ...

T2 Biosystems (TTOO) -20% despite strong Q4 & FY20 prelims.AIkido Pharma (AIKI) -18%.Seanergy Maritime Holdings (SHIP) -18%.Celsion CLSN -15%.Recon Technology (RCON) -15%.TransEnterix (TRXC) -14% after $69.25M capital raise.Ocugen (OCGN) -14%.BIOLASE (BIOL) -15%.P...

Scopus BioPharma (SCPS) has priced its public offering of 1M common shares at $9.00/share, for proceeds of $9M.Underwriters' over-allotment is an additional 150K shares. Proceeds will be used for further development of company's lead drug candidate, including in combination with checkpoint in...